CN119546610A - 作为HPK1抑制剂的四氢吡啶并[3,4-d]嘧啶 - Google Patents

作为HPK1抑制剂的四氢吡啶并[3,4-d]嘧啶 Download PDF

Info

Publication number
CN119546610A
CN119546610A CN202380052662.0A CN202380052662A CN119546610A CN 119546610 A CN119546610 A CN 119546610A CN 202380052662 A CN202380052662 A CN 202380052662A CN 119546610 A CN119546610 A CN 119546610A
Authority
CN
China
Prior art keywords
mmol
group
pyrido
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380052662.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·图雷
B·李
C·尼古
王艳平
T·约翰逊
洛佩兹 A·恩祖
A·恩祖洛佩兹
Y·萧
E·弗丽斯
M·迪波托
S·古勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN119546610A publication Critical patent/CN119546610A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380052662.0A 2022-05-10 2023-05-04 作为HPK1抑制剂的四氢吡啶并[3,4-d]嘧啶 Pending CN119546610A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263340191P 2022-05-10 2022-05-10
US63/340,191 2022-05-10
US202263383190P 2022-11-10 2022-11-10
US63/383,190 2022-11-10
PCT/US2023/066601 WO2023220541A1 (en) 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors

Publications (1)

Publication Number Publication Date
CN119546610A true CN119546610A (zh) 2025-02-28

Family

ID=86688794

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380052662.0A Pending CN119546610A (zh) 2022-05-10 2023-05-04 作为HPK1抑制剂的四氢吡啶并[3,4-d]嘧啶

Country Status (9)

Country Link
US (1) US20240025922A1 (enExample)
EP (1) EP4522618A1 (enExample)
JP (1) JP2025521083A (enExample)
CN (1) CN119546610A (enExample)
AU (1) AU2023267747A1 (enExample)
CA (1) CA3250387A1 (enExample)
IL (1) IL316818A (enExample)
TW (1) TW202400612A (enExample)
WO (1) WO2023220541A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210407A1 (en) * 2024-04-01 2025-10-09 Merck Patent Gmbh (7-{1h,2h,3h-pyrido [2,3-b][1,4]oxazin-7-yl}-5h,6h,7h,8h-pyrido[3,4-d]pyrimidin-2-yl)amine derivatives as bifunctional degraders of hpk1 for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010302A (es) * 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.

Also Published As

Publication number Publication date
TW202400612A (zh) 2024-01-01
CA3250387A1 (en) 2023-11-16
AU2023267747A1 (en) 2024-11-07
JP2025521083A (ja) 2025-07-08
IL316818A (en) 2025-01-01
WO2023220541A1 (en) 2023-11-16
US20240025922A1 (en) 2024-01-25
EP4522618A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US20240270747A1 (en) Heteroaryl pyridone and aza-pyridone compounds
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
RU2617405C2 (ru) Пиридоновые и азапиридоновые соединения и способы применения
EP3601259A1 (en) Isoquinolines as inhibitors of hpk1
EP4522618A1 (en) Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors
BR112014010459B1 (pt) Compostos e composição farmacêutica
BR122020017743B1 (pt) Processo para fabricação de uma composição farmacêutica e uso de uma composição farmacêutica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination